HIMS & HERS HEALTH ($HIMS) posted quarterly earnings results on Monday, May 5th. The company reported earnings of $0.20 per share, beating estimates of $0.12 by $0.08. The company also reported revenue of $586,010,000, beating estimates of $548,967,315 by $37,042,685.
You can see Quiver Quantitative's $HIMS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HIMS & HERS HEALTH Insider Trading Activity
HIMS & HERS HEALTH insiders have traded $HIMS stock on the open market 149 times in the past 6 months. Of those trades, 2 have been purchases and 147 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 48 sales selling 1,403,156 shares for an estimated $45,621,202.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 28 sales selling 414,042 shares for an estimated $13,030,935.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 29 sales selling 360,655 shares for an estimated $10,848,741.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 13 sales selling 353,166 shares for an estimated $10,191,707.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 17 sales selling 154,822 shares for an estimated $5,087,670.
- PATRICK HARRISON CARROLL (Chief Medical Officer) has made 0 purchases and 3 sales selling 42,994 shares for an estimated $1,262,996.
- DAVID B WELLS sold 40,000 shares for an estimated $1,199,584
- IRENE BECKLUND (PAO) has made 0 purchases and 8 sales selling 29,488 shares for an estimated $978,766.
- ANJA MANUEL has made 2 purchases buying 5,000 shares for an estimated $132,259 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HIMS & HERS HEALTH Hedge Fund Activity
We have seen 250 institutional investors add shares of HIMS & HERS HEALTH stock to their portfolio, and 181 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FARALLON CAPITAL MANAGEMENT LLC added 8,364,000 shares (+64338.5%) to their portfolio in Q4 2024, for an estimated $202,241,520
- BIT CAPITAL GMBH removed 6,151,360 shares (-80.1%) from their portfolio in Q4 2024, for an estimated $148,739,884
- BLACKROCK, INC. removed 5,862,886 shares (-19.5%) from their portfolio in Q1 2025, for an estimated $173,248,281
- GOLDMAN SACHS GROUP INC added 4,488,389 shares (+425.3%) to their portfolio in Q4 2024, for an estimated $108,529,246
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 4,145,305 shares (+192.0%) to their portfolio in Q4 2024, for an estimated $100,233,474
- STATE STREET CORP added 3,146,380 shares (+68.0%) to their portfolio in Q4 2024, for an estimated $76,079,468
- ICONIQ CAPITAL, LLC added 2,874,769 shares (+inf%) to their portfolio in Q4 2024, for an estimated $69,511,914
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HIMS & HERS HEALTH Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Sell" rating on 04/02/2025
- Needham issued a "Buy" rating on 02/25/2025
- Canaccord Genuity issued a "Buy" rating on 02/19/2025
- UBS issued a "Underperform" rating on 12/20/2024
To track analyst ratings and price targets for HIMS & HERS HEALTH, check out Quiver Quantitative's $HIMS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
